clinical trial · NCT05101317
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated Pain
Hope Medicine (Nanjing) Co., Ltd·phase2·completed·n = 142
EndometriosisHMI-115Placebo
brief summary
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
started
Oct 11, 2021
primary completion
Sep 26, 2024
completion
Mar 19, 2025
last updated
Jan 21, 2026
detailed description
This study aims to evaluate the safety and efficacy of HMI-115 versus a placebo in pre-menopausal women with moderate to severe Endometriosis associated pain.
The study will determine the safety and efficacy of HMI 115 at 3 dose levels.
official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol